.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Teva
Chinese Patent Office
Julphar
Farmers Insurance
Healthtrust
US Army
Express Scripts
McKesson
Johnson and Johnson

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Chymopapain composition and method for its use
Abstract:An improved method for treating an intervertebral spinal disc in a mammalian subject which disc exhibits an abnormal condition, characterized by a reduced risk of toxic effect to the subject is provided which comprises, injecting in said disc an amount of a pharmaceutically acceptable solution of a purified chymopapain essentially free of proteolytically inactive and/or toxic protein components, said purified chymopapain being used in an amount sufficient to selectively dissolve the nucleus pulposus of said disc. Pharmaceutical compositions are also provided for said method which include a purified proteolytically active lyophilized chymopapain, essentially free of proteolytically inactive and toxic components, and an activating amount of a pharmaceutically acceptable reducing agent.
Inventor(s): Smith; William S. (Libertyville, IL)
Assignee: Smith Laboratories, Inc. (Rosemont, IL)
Filing Date:Mar 26, 1984
Application Number:06/593,158
Claims:1. A method of treating an intervertebral spinal disc to dissolve the nucleus pulposus in a mammalian subject which disc exhibits an abnormal condition, characterized by a reduced risk of toxic effect to the mammalian subject, which method comprises the step of injecting into said disc an amount of pharmaceutically acceptable solution of a purified chymopapian essentially free of proteolytically inactive and toxic protein components, said purified chymopapain also characterized by the absence of precipitate formation when a 10% weight/volume solution is acidified with hydrochloric acid followed by treatment with barium chloride, said purified chymopapain being used in amounts sufficient to selectively dissolve the nucleus pulposus of said disc.

2. A method according to claim 1 wherein the abnormal disc is a herniated intervertebral disc.

3. A method of treating a herniated intervertebral spinal disc in an mammalian subject which comprises the steps of:

(a) inserting the needle into said disc;

(b) confirming the placement of said needle by means of x-ray and

(c) injecting into said disc an amount of a pharmaceutically acceptable aqueous solution of a relatively non-toxic, purified chymopapain characterized as essentially free of proteolytically inactive compounds and bisulfite and by its failure to form a precipitate when an acidified solution thereof is treated with barium chloride reagent to selectively dissolve the said disc.

4. A pharmaceutical composition consisting essentially of a purified proteolytically active chymopapain admixture of chymopapain fractions I and II and characterized by the absence of precipitate formation when a 10% weight/volume solution is acidified with hydrochloric acid followed by treatment with barium chloride.

5. A pharmaceutical composition according to claim 4 wherein the purified chymopapain is an admixture of chymopapain fractions I and II and is essentially free of proteolytically inactive components.

6. A pharmaceutical composition according to claim 4 in dosage unit form wherein the purified chymopapain is an admixture of proteolytically active chymopapain fractions I and II.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
McKesson
Teva
Dow
Cerilliant
Fish and Richardson
Novartis
Harvard Business School
QuintilesIMS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot